To provide a culture supernatant preparation which has excellent biocompatibility and contains a large quantity of specific genes or proteins. A method for producing the culture supernatant preparation including: a first culturing step of culturing cells to a confluent state using a first medium; a second culturing step of culturing the cells using a second medium that is different from the first medium after the first culturing step; and a culture supernatant preparation obtaining step of obtaining the culture supernatant preparation including the second medium after the second culturing step, the second medium including a calcium ion and a buffering agent.

The present invention provides a serum-free endothelial cell differentiation culture medium comprising (a) a basal culture medium and (b) an endothelial cell differentiation combination of EGF, FGF and VEGF protein, wherein the amount of EGF is higher than the amount of FGF protein. The present invention further provides a process for the preparation of cellular aggregate suspensions comprising differentiated endothelial cells from dental stem cells using the serum-free medium, as well as the use of the resulting suspension in therapy.

Provided are a cell growth method including serum-free culture of somatic cells sowed in a cell growth medium containing a culture supernatant of dental pulp stem cells, wherein the somatic cells exclude physically or physiologically defected somatic cells, is a novel cell growth method for serum-free culture of somatic cells.

A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. The invention also relates to a process for preparing the neuroprotective composition, as well as the medical uses of the neuroprotective composition in the treatment of neurological diseases associated with neuronal damage, including subarachnoid hemorrhage and Parkinson's disease.

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. The invention also relates to a process for preparing the neuroprotective composition, as well as the medical use of the neuroprotective composition in the treatment of Parkinson's disease.

A method of generating a population of cells useful for treating a nerve disease or disorder in a subject, the method comprising up-regulating a level of at least one exogenous miRNA in mesenchymal stem cells (MSCs) and/or down-regulating a level of at least one miRNA using a polynucleotide agent that hybridizes to the miRNA, thereby generating the population of cells useful for treating the nerve disease or disorder. Isolated populations of cells with an astrocytic phenotype generated thereby and uses thereof are also provided.

To provide a culture supernatant preparation which has excellent biocompatibility and contains a large quantity of specific genes or proteins. A method for producing the culture supernatant preparation including: a first culturing step of culturing cells to a confluent state using a first medium; a second culturing step of culturing the cells using a second medium that is different from the first medium after the first culturing step; and a culture supernatant preparation obtaining step of obtaining the culture supernatant preparation including the second medium after the second culturing step, the second medium including a calcium ion and a buffering agent.

A method of preparing a reprogramming induced pluripotent stem cell from a human-derived somatic cell using a fusion protein in which a reprogramming inducing factor and cell permeable peptide (CPP) are fused, and a fusion protein in which a reprogramming inducing factor and a cell permeable peptide are fused are disclosed. According to the present invention, the induced pluripotent stem cell having high efficiency and high stability can be prepared by maximizing the effect of the reprogramming inducing transcription factor beyond the existing viral peptide transporter, in inducing the reprogramming of the somatic cell.

Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1aCD5 or CD34+CD7+CD1aCD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.